ChabioTech Appoints Lee Hyun-jung as Co-CEO to Strengthen R&D

Hyun-Jung Lee, Newly Appointed Co-CEO of Cha Biotech
[Photo by Cha Biotech]

Cha Biotech announced on the 31st that its board of directors held a meeting and changed the sole representative system of Osanghoon to a dual representative system with Osanghoon and Lee Hyunjung. The plan is to strengthen competitiveness and increase efficiency through rapid decision-making in the business and research & development (R&D) sectors to maximize synergy.

The new representative is a clinical development expert with experience in global new drug development and a specialist in obstetrics and gynecology. He has led anticancer drug development for 20 years at global pharmaceutical companies such as Pfizer, Eli Lilly, Baxalta, Shire (now Takeda), and Samyang Biopharm USA, and joined Cha Biotech as president of the R&D division in December last year.

Representative Lee will oversee the research and development division of Cha Biotech and Cha Biotech Group. Based on the 'Industry-Academia-Research-Hospital Ecosystem,' where CHA University, the Comprehensive Research Institute, CHA Hospital, and group affiliates collaborate organically, he plans to continuously develop pipelines and strengthen cell therapy R&D capabilities to expedite commercialization as much as possible.

Representative Oh plans to focus on expanding the global business and profitability of the business division, including cord blood storage, genome analysis and diagnostics, future-oriented well-aging healthcare global expansion, and domestic and international cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) business, aiming to establish a stable financial structure.

This content was produced with the assistance of AI translation services.